Latest Breaking News On - Montes archimedes acquisition corp - Page 10 : comparemela.com

Dive Brief: Roivant Sciences, an unusual holding company with roughly a dozen biotech subsidiaries, will go public through a merger with a blank-check entity in a deal that values the company at $7.3 billion. Roivant will get $611 million in cash by merging with Montes Archimedes Acquisition Corp., a special purpose acquisition company, or SPAC, formed by Patient Square Capital. That figure includes $411 million already in a Montes Archimedes Trust and a commitment by Patient Square and other investors to buy $200 million in Roivant stock at $10 apiece. The agreement will leave Roivant, whose subsidiaries have had both high-profile successes as well as failures, with $2.3 billion in cash upon going public. The deal, one of the larger SPAC mergers in biotech, comes amid signs the boom in such deals may be waning. Returns are down, while many SPACs are in competition for takeover targets. Federal oversight, meanwhile, appears to be increasing.

Sumitomo dainippon pharmaVivek ramaswamyMatthew glineAxovant sciencesExchange commissionRoivant sciencesPuretech healthMontes archimedes acquisition corpMontes archimedesCentessa pharmaceuticalsHealth sciences acquisition corpDive briefPatient squareMontes archimedes trustSumitomo dainipponSio gene therapies